Imaging Airflow Behind Mucus Plugs in Lung Disease With Xenon MRI
Uses xenon MRI to study airflow in lung areas behind mucus plugs in adults.
Plain-language title generated from the registry record
Registry title: Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
Key facts
- Where
- Kansas City, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06985225, who can take part
Where in United States
- University of Kansas Medical CenterKansas City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Kansas Medical Center
- Trial code
- NCT06985225
- Record updated
- 1 July 2026
- Original description
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.Read full original descriptionShow less
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with muco-obstructive pulmonary disease. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.
Inclusion: Adequate completion of informed consent process with written documentation; Patients 18 - 65 years old; • Physician diagnosis of muco-obstructive pulmonary disease, including cystic fibrosis, severe asthma, chronic obstructive pulmonary disease, or non-cystic fibrosis bronchiectasis for > 1 year; Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs.
Exclusion: Respiratory tract infection within the 4 weeks prior to Visit 1; One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1; ER visit related to pulmonary condition within the previous 4 weeks of Visit 1; Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.); Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study; Conditions that will prohibit MRI scanning determined by the MRI safety screening; Body mass index (BMI) > 30 at Visit 1; Resting O2 saturation <90% with maximum supplemental O2 delivered by nasal canula; Positive urine pregnancy test; Unable or unlikely to complete study assessments in the opinion of the Investigator; Study intervention poses undue risk to patient in the opinion of the Investigator.